Bridging the Gap: Exploring Challenges in the Transition from Psilocybin-Assisted Therapy to Traditional Medicine

Written By Christian Schocke

Study Title: Bridging the Gap: Exploring Challenges in the Transition from Psilocybin-Assisted Therapy to Traditional Medicine

Plain Language Summary: This Swinburne University study explores the challenges faced by past participants of psilocybin-assisted therapy (PAT) clinical trials when they transition back to traditional healthcare. Through an anonymous online survey, we aim to gather insights that will help inform the development of better integration support for future patients.

Lead Researcher Name: Prof. Susan Rossell, Swinburne University of Technology

Other Researchers / Team (optional): Thomas Curtain, Master of Psychology (Clinical) Student, Swinburne University of Technology

Institution / Organization: Swinburne University of Technology

Ethics Approval Number (optional but encouraged): HREC Ref: 20258257-22378

Recruitment Start Date: 20 September 2025

Recruitment End Date:

Trial Phase: Case Study

Substance Focus: Psilocybin

Therapeutic Model Used : CBT, Somatic, IFS

Is this an RCT?: No

Follow-up Psychedelic Dosing Arm Included?: No

Who Can Participate?: This study is open to all adults (18+) who have previously participated in a psilocybin clinical trial.

Exclusion Criteria: Under 18 years of age; have not previously participated in a clinical trial involving psilocybin.

Number of Participants Needed: Up to 200.

Location of Participants: International

Preferred Participant Demographics: Other

Please Specify: This study is open to all adults (18+) who have previously participated in a psilocybin clinical trial, regardless of gender, ethnicity, or background.

Type of Participation: Survey

Time Commitment: 15 - 30 minute survey.

Compensation / Reimbursement: Participation is voluntary and not compensated.

Format: Online

Technology or Tools Needed: A device with internet access and a web browser.

Consent Process Summary: Participants will be presented with a full Explanatory Statement on the first page of the online survey. Consent is implied by their action of reading the statement and choosing to proceed with the anonymous survey.

Contact Email: 103408429@student.swin.edu.au

Phone Number:

Sign-Up / EOI Link : https://swinuw.au1.qualtrics.com/jfe/form/SV_aWyopDoGxf00j3w

Website or Social Media Link (optional):

Accessibility Information:

Cultural Safety Considerations:

Confidentiality & Privacy Statement: This study is completely anonymous. No personally identifiable information (such as name, email, or IP address) will be collected. All data is collected securely via the Swinburne University Qualtrics platform and will be reported only in aggregate, de-identified form to protect participant privacy. The study adheres to the ethical guidelines approved by the Swinburne HREC.

Study Focus / Topic:

Target Population: Adults, older adults. This study is open to all adults (18+) who have previously participated in a psilocybin clinical trial, regardless of gender, ethnicity, or background.

Urgency Level: Seeking Participants Now

Study Methodology Type: Mixed

Ethics Committee Details: Swinburne University Human Research Ethics Committee (SUHREC)

Funding Body / Sponsor (if any): Unfunded Master of Psychology (Clinical) thesis project.

Trial Location: Virtual

Christian Schocke